Overview
Epinomics develops a platform to decode the epigenome by mapping chromatin accessibility with ATAC-seq, helping researchers in pharma, biotech, and academia study gene regulation and discover biomarkers. The method uses the ATAC-seq assay on a small number of cells and combines it with an analytics engine to interpret regulatory regions and link them to disease biology and treatment responses. Its edge comes from high-sensitivity epigenomic profiling and integrated data analysis, enabling more precise questions about regulation and biomarkers than older approaches. The company aimed to speed up therapeutic development and biomarker discovery, and its team and technology were later acquired by 10x Genomics to strengthen their single-cell ATAC solutions.
Work here?Claim your company
Simplify's take
What believers are saying
- 10x launched Atera and Sentira in November 2026, proving active platform investment.
- Epi ATAC and Epi Multiome remain fully commercialized on Chromium X in October 2026.
- Q3 2026 gross margin reached 75%, giving 10x room to fund epigenomics growth.
What critics are saying
- 10x Genomics' Q3 2026 revenue grew only 1%, signaling sluggish demand.
- Illumina, Parse Biosciences, and emerging multiomics platforms keep compressing ATAC-seq pricing.
- If Epi products stall, 10x's epigenetics franchise remains a niche add-on, not a category leader.
What makes Epinomics unique
- Epinomics' ATAC-seq IP became 10x Genomics' Epi ATAC and Epi Multiome backbone.
- Howard Chang and William Greenleaf anchored Stanford-origin epigenetics credibility and scientific legitimacy.
- Single-cell chromatin accessibility plus gene expression creates deeper biology than sequencing alone.
Help us improve and share your feedback! Did you find this helpful?